Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/1/2018
SIETES contiene 92183 citas

 
 
 1 a 20 de 1921 siguiente >>
Presentar resultados
Seleccionar todas
3.Tiene citas relacionadas Cita con resumen
Jonker CJ, van den Berg HM, Kwa MSG, Hoes AW, Mol PGM. Registries supporting new drug applications. Pharmacoepidemiol Drug Saf 2017;27:1451-7. [Ref.ID 102187]
4. Cita con resumen
Jongsma HE, Gayer-Anderson C, Lasalvia A, Quattrone D, Mulé A, Szoke A, Selten J-P, Turner C, Arango C, Tamcone I, Berardt D, Tortelli A, Llorca P-M, de Haan L, Bobes J, Bernardo M, Sanjuán J, Santos JL, Arrojo M, Del-Ben CM, Menezes PR, Murray RM, Rutten BP, Jones PB, Van Os J, Morgan C, Kirkbride JB, for the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions Work Package 2 (EU-GEI WP2) Group. Treated incidence of psychotic disorders in the multinational EU-GEI study. JAMA Psychiatry 2017:6 de diciembre. [Ref.ID 102177]
5. Cita con resumen
Anónimo. Dutch health minister considers compulsory license over drug prices. DIA Daily 2017:1. [Ref.ID 102148]
6. Cita con resumen
Casassus B. Contraception implant removed from global market. Lancet 2017;390:1576. [Ref.ID 102079]
7. Cita con resumen
Santoro A, Genov G, Spooner A, Raine J, Arlett P. Promoting and protecting public health: how the European Union pharmacovigilance system works. Drug Saf 2017;40:855-69. [Ref.ID 102075]
8. Cita con resumen
Edwards IR. A new Erice report considering the safety of medicines in the 21st Century. Drug Saf 2017;40:845-9. [Ref.ID 102074]
9.Enlace a cita original Cita con resumen
MacDonald A. EU drugs watchdog staff favor move to Amsterdam: sources. Reuters Health News 2017:1. [Ref.ID 102067]
10. Cita con resumen
11. Cita con resumen
de Vries ST, van der Sar MJM, Cupelli A, Baldelli I, Coleman AM, Montero D, Sipic I, Andric A, Wennberg A, Ahlqvist-Rastad J, Denig P, Mol PGM, On behalf of SCOPE Work Package 6. Communication on safety of medicines in Europe: current practices and general practitioners’ awareness and preferences. Drug Saf 2017;40:729-42. [Ref.ID 101983]
12. Cita con resumen
Kurz X. Advancing regulatory science, advancing regulatory practice. Pharmacoepidemiol Drug Saf 2017;26:722-6. [Ref.ID 101964]
13. Cita con resumen
Wallerstedt SM, Fastbom J, Linke J, Vitols S. Long-term use of proton pump inhibitors and prevalence of disease - and drug-related reasons for gastroprotection — A cross-sectional population-based study. Pharmacoepidemiol Drug Saf 2017;26:9-16. [Ref.ID 101946]
14.Enlace a cita originalTiene citas relacionadas Cita con resumen
Bouvy JC, Blake K, Slattery J, De Bruin ML, Arlett P, Kurz X. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005–2013. Pharmacoepidemiol Drug Saf 2017;26:26 de marzo. [Ref.ID 101903]
15. Cita con resumen
Anónimo. EMA’s CHMP recommends approval of biosimilar insulin lispro. DIA Daily 2017:2. [Ref.ID 101598]
17. Cita con resumen
18. Cita con resumen
Anónimo. MSF, Medecins du Monde challenge Gilead’s sofosbuvir patent. DIA Daily 2017:1. [Ref.ID 101490]
19. Cita con resumen
Anónimo. Rivaroxaban: agranulocytoses et syndromes de Stevens-Johnson. Prescrire 2017;37:187. [Ref.ID 101456]
20. Cita con resumen
Spelsberg A , Prugger C , Doshi P , Ostrowski K , Witte T , Hüsgen D , Keil U , for the Working Group on Health and Working Group on Freedom of Information Transparency International Deutschland eV. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ 2017;356:j337. [Ref.ID 101390]
Seleccionar todas
 
 1 a 20 de 1921 siguiente >>